Risk factors associated with the incidence and time to onset of lapatinib-induced hepatotoxicity

Formation of reactive metabolites and management of tyrosine kinase inhibitor-induced hepatotoxicity: a literature review

(2014) Yi Ling Teo et al.   Expert Opinion on Drug Metabolism & Toxicology

Hepatotoxicity of Tyrosine Kinase Inhibitors: Clinical and Regulatory Perspectives

(2013) Rashmi R. Shah et al.   DRUG SAFETY

Effect of CYP3A4 inducer dexamethasone on hepatotoxicity of lapatinib: clinical and in vitro evidence

(2012) Yi Ling Teo et al.   BREAST CANCER RESEARCH AND TREATMENT

Drug Absorption Interactions Between Oral Targeted Anticancer Agents and PPIs: Is pH-Dependent Solubility the Achilles Heel of Targeted Therapy?

(2012) N R Budha et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Drug–Drug Interaction Potential of Marketed Oncology Drugs: In Vitro Assessment of Time-Dependent Cytochrome P450 Inhibition, Reactive Metabolite Formation and Drug–Drug Interaction Prediction

(2012) Jane R. Kenny et al.   PHARMACEUTICAL RESEARCH

HLA-DQA1*02:01 Is a Major Risk Factor for Lapatinib-Induced Hepatotoxicity in Women With Advanced Breast Cancer

(2011) Colin F. Spraggs et al.   JOURNAL OF CLINICAL ONCOLOGY

Managing the challenge of chemically reactive metabolites in drug development

(2011) B. Kevin Park et al.   NATURE REVIEWS DRUG DISCOVERY

Mechanism-Based Inactivation of Cytochrome P450 3A4 by Lapatinib

(2010) W. C. Teng et al.   MOLECULAR PHARMACOLOGY

Very important pharmacogene summary

(2010) Laura M. Hodges et al.   Pharmacogenetics and Genomics

Effects of ketoconazole and carbamazepine on lapatinib pharmacokinetics in healthy subjects

(2009) Deborah A. Smith et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer

(2008) Henry L. Gomez et al.   JOURNAL OF CLINICAL ONCOLOGY